Goldman Sachs Reinitiates Coverage on Madrigal Pharmaceuticals (MDGL) with Buy Rating and $704 Price Target

gurufocus.com · 2026-09-24

On September 24, 2026, Goldman Sachs restarted its analysis of Madrigal Pharmaceuticals Inc (NASDAQ: MDGL), assigning a Buy rating and setting a price target of

Read the full story at gurufocus.com →